Key Takeaways
- • Osteoboost Health closed an $8 million Series funding round led by Ambit Health Ventures, with participation from new investors Emmeline Ventures and Disrupt Health Impact Fund, plus existing backers Esplanade Ventures and Portfolia.
- • The company's FDA-cleared prescription wearable device has achieved adoption among more than 2,500 physicians and targets the 44 million Americans living with low bone density, a precursor to osteoporosis.
- • Osteoboost's capital infusion will fund three strategic priorities: manufacturing scale-up, clinical research expansion, and commercial distribution broadening for its non-drug vibration therapy treatment aimed at postmenopausal women with osteopenia.
- • The device represents the first and only FDA-cleared, non-drug treatment clinically proven to address low bone density in postmenopausal women, positioning it as a differentiated solution in a market with limited preventive options.
- • CEO Laura Yecies emphasized the market opportunity in early intervention during menopause, when bone density declines accelerate, rather than waiting for osteoporosis diagnosis when treatment becomes costlier and more complex.
Summary
Osteoboost Health announced the close of an $8 million financing round, marking a significant capital infusion for the Redwood City, California–based medical device company. The round was led by Ambit Health Ventures and included participation from new investors Emmeline Ventures and Disrupt Health Impact Fund, alongside existing shareholders Esplanade Ventures and Portfolia.
The company manufactures a Class II prescription wearable device designed to treat low bone density through targeted, low-magnitude vibration therapy. Worn low around the hips and over the sacrum, the device delivers precisely calibrated vibrations to the lumbar spine and hips—regions most vulnerable to fracture. Osteoboost is the first and only FDA-cleared, non-drug treatment clinically proven to treat low bone density in postmenopausal women with osteopenia, positioning it as a differentiated therapeutic approach in a market with limited preventive options.
The company has achieved notable commercial traction prior to this funding, with more than 2,500 physicians having prescribed Osteoboost to date. This adoption level underscores clinical acceptance among practitioners managing bone health in at-risk populations. The market opportunity is substantial: nearly 10 million Americans have osteoporosis, while another 44 million live with low bone density. Few non-pharmaceutical interventions exist for women to proactively address age-related bone loss, particularly during menopause when bone density declines most rapidly.
Osteoboost plans to deploy the $8 million toward three core initiatives: scaling manufacturing capacity, expanding clinical research programs, and broadening commercial reach. CEO Laura Yecies emphasized the strategic importance of early intervention and prevention during the menopause window, noting that bone health deterioration develops "silently over many years" before osteoporosis diagnosis, when treatment becomes significantly more costly and complex. This positioning aligns the company's therapeutic strategy with a shift toward preventive care and earlier intervention in bone health management.
The company manufactures a Class II prescription wearable device designed to treat low bone density through targeted, low-magnitude vibration therapy. Worn low around the hips and over the sacrum, the device delivers precisely calibrated vibrations to the lumbar spine and hips—regions most vulnerable to fracture. Osteoboost is the first and only FDA-cleared, non-drug treatment clinically proven to treat low bone density in postmenopausal women with osteopenia, positioning it as a differentiated therapeutic approach in a market with limited preventive options.
The company has achieved notable commercial traction prior to this funding, with more than 2,500 physicians having prescribed Osteoboost to date. This adoption level underscores clinical acceptance among practitioners managing bone health in at-risk populations. The market opportunity is substantial: nearly 10 million Americans have osteoporosis, while another 44 million live with low bone density. Few non-pharmaceutical interventions exist for women to proactively address age-related bone loss, particularly during menopause when bone density declines most rapidly.
Osteoboost plans to deploy the $8 million toward three core initiatives: scaling manufacturing capacity, expanding clinical research programs, and broadening commercial reach. CEO Laura Yecies emphasized the strategic importance of early intervention and prevention during the menopause window, noting that bone health deterioration develops "silently over many years" before osteoporosis diagnosis, when treatment becomes significantly more costly and complex. This positioning aligns the company's therapeutic strategy with a shift toward preventive care and earlier intervention in bone health management.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.